
BioNTech SE (BNTX) Stock Forecast & Price Target
BioNTech SE (BNTX) Analyst Ratings
Bulls say
BioNTech is well-positioned for growth, evidenced by the promising results from BNT326 and its favorable comparison to competitive treatments in the EGFR+ NSCLC space, which underscores the potential for accelerated approval. The company's oncology pipeline, including innovative drug classes and strong early-phase efficacy results, reveals significant survival benefits, likely enhancing its market appeal as a fully integrated oncology company. Additionally, with a robust cash position of approximately €16.7 billion, BioNTech is financially equipped to support its development initiatives and capitalize on multiple upcoming catalysts.
Bears say
BioNTech is facing a negative outlook primarily due to anticipated declines in COVID-related revenues, which are projected to fall significantly over the coming years, leading to 24% and 18% reductions in fiscal years 2026 and 2025, respectively. Additionally, manufacturing challenges related to personalized therapeutics and potential negative data or slow market adoption for various oncology candidates could further impede the company’s revenue generation and impact future forecasts. The recent departure of key leadership figures, CEO Ugur Sahin and CMO Ozlem Tureci, also raises concerns about the company’s strategic direction and stability, contributing to a decline of over 20% in share value since the announcement.
This aggregate rating is based on analysts' research of BioNTech SE and is not a guaranteed prediction by Public.com or investment advice.
BioNTech SE (BNTX) Analyst Forecast & Price Prediction
Start investing in BioNTech SE (BNTX)
Order type
Buy in
Order amount
Est. shares
0 shares